7 min read · May 2026
Oral Wegovy vs Compounded Semaglutide: 2026 Comparison
Key comparison: Oral Wegovy (semaglutide 25mg pill) launched January 2026 at $299/month for the target dose. Compounded injectable semaglutide runs $147-$299/month. Both contain semaglutide — but the delivery method, FDA status, and regulatory risk profiles are very different.
For the first time, patients have a genuine pill-versus-shot decision to make within the same active ingredient. Here's the honest comparison.
Head-to-Head Comparison
| Factor | Oral Wegovy (Pill) | Compounded Injectable |
|---|---|---|
| FDA Status | FDA-approved | Not FDA-approved |
| Active Ingredient | Semaglutide | Semaglutide |
| Target Dose | 25mg daily pill | 2.4mg weekly injection |
| Weight Loss (trials) | ~16.6% (OASIS 4) | ~15-17% (STEP trials) |
| Pricing | $149-$299/mo cash | $147-$350/mo telehealth |
| Medicare Eligible | Yes (BALANCE, $50/mo) | No |
| Refrigeration | Not required | Required before first use |
| Travel Convenience | High (carry a pill) | Moderate (cold chain needed) |
| Regulatory Risk | None | High (503B ban pending) |
When Oral Wegovy Makes More Sense
Needle aversion. If you genuinely cannot or will not do weekly injections, the pill removes the biggest compliance barrier.
Medicare eligibility. Under the BALANCE Model (July 2026), oral Wegovy costs $50/month through Medicare. No compounded product qualifies for this pricing.
Travel lifestyle. No cold storage, no needles in carry-on, no TSA conversations. Take it like a daily vitamin.
Long-term security. Brand-name medications face zero regulatory risk. Your supply chain doesn't depend on a comment period or a court ruling.
When Compounded Injectable Makes More Sense
Cost sensitivity without Medicare. For cash-pay patients, compounded semaglutide at $147-$199/month can be significantly cheaper than oral Wegovy's $299/month target dose.
Dose flexibility. Compounded formulations allow more granular dose titration than standardized brand-name steps.
Tirzepatide preference. If you want a dual-agonist (GLP-1 + GIP), compounded tirzepatide is available. Oral tirzepatide is not yet on the market.
The Bottom Line
Neither option is universally "better." Oral Wegovy wins on convenience, regulatory security, and Medicare eligibility. Compounded injectable wins on price flexibility and dose customization. Your specific circumstances — insurance status, needle tolerance, budget, travel habits — determine the right choice.
Sesame Care
Prescribes oral Wegovy and other FDA-approved brand-name GLP-1 medications.
Embody
Injectable compounded semaglutide with physician-guided titration.
Compounded medications are not FDA-approved.
Learn More Paid linkCompare GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- Novo Nordisk. Oral Wegovy prescribing information. January 2026.
- OASIS 4 trial. Oral semaglutide efficacy data. NEJM, 2025.
- FDA. Compounded medications enforcement guidance. 2026.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.